Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas

Journal of Immunotherapy

Volumn 35, Issue 8, 2012, Pages 629-640

  Davis, Marcherie ^a   Conlon, Kevin ^a,b   Bohac, Gerald C ^a,c   Barcenas, John ^a   Leslie, William ^a   Watkins, Latanja ^a   Lamzabi, Ihab ^a   Deng, Youping ^d   Li, Yan ^d   Plate, Janet M D ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b AMGEN INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d RUSH CANCER INSTITUTE   (United States)

Author keywords

B7 H3; innate immunity; interferon gamma (IFNg); interleukin 2 (IL 2); NK cells; pancreatic cancer; pemetrexed

Indexed keywords

CD134 ANTIGEN; CD16 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD45RO ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 2; ONCOPROTEIN; PEMETREXED; PROTEIN B7 H3; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CD8+ T LYMPHOCYTE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFECT; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; INTERFERON PRODUCTION; MALE; MEMORY T LYMPHOCYTE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; PANCREAS ADENOCARCINOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ADAPTIVE IMMUNITY; ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B7 ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; GLUTAMATES; GUANINE; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTE SUBSETS;

EID: 84866681005     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31826c8a4f     Document Type: Article

References (37)

1. Cancer Facts & Figures 2011. American Cancer Society. 2011;1-58. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/ documents/document/acspc-029771.pdf.
2. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363:1049-1057. (Pubitemid 38410779)
3. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer. 1997;33(suppl 1):S18-S22.
4. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413. (Pubitemid 27251144)
5. Rothenberg ML. New developments in chemotherapy for patients with advanced pancreatic cancer. Oncology. 1996;10: 18-22. (Pubitemid 26323230)
6. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-Fu-refractory pancreas cancer. Ann Oncol. 1996;7:347-353. (Pubitemid 26246785)
7. Berlin JD, Rothenberg M. Chemotherapy for resectable and advanced pancreatic cancer. Oncology. 2001;15:1241-1249; discussion 1254-1264.
8. Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-Tolerizing host tumorspecific CD8 T cells. J Immunol. 2003;170:4905-4913. (Pubitemid 36554719)
9. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 2003;63:4490-4496. (Pubitemid 36951021)
10. Plate JMD, Harris JE. Immune cell functions in pancreatic cancer. Crit Rev Immunol. 2000;20:375-392. (Pubitemid 32104092)
11. Miyazawa M, Ohsawa R, Tsunoda T, et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010;101:433-439.
12. Morse MA, Hall JR, Plate JM. Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer. Expert Opin Biol Ther. 2009;9:331-339.
13. Adjei AA. Pemetrexed (Alimta), a novel multitargeted antineoplastic agent. Clin Cancer Res. 2004;10:4276s-4280s. (Pubitemid 38812462)
14. Courtemanche C, Elson-Schwab I,Mashiyama ST, et al. Folate deficiency inhibits the proliferation of primary human Cd8+ T lymphocytes in vitro. J Immunol. 2004;173:3186-3192. (Pubitemid 39142025)
15. Gross RL, Reid JV, Newberne PM, et al. Depressed cellmediated immunity in megaloblastic anemia due to folic acid deficiency. Am J Clin Nutr. 1975;28:225-232.
16. Schroecksnade K, Frick B, Wirleitner B, et al. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol. 2004;5:107-118. (Pubitemid 38410598)
17. Kim YI, Hayek M, Mason JB, et al. Severe folate deficiency impairs natural killer cell-mediated cytotoxicity in rats. J Nutr. 2002;132:1361-1367. (Pubitemid 34606477)
18. Tsang KY, Hynes JB, Fudenberg HH, et al. Effects of three new folate antagonists on human breast adenocarcinoma cells in vitro and on immune responses in vivo. Chemotherapy. 1984;30:61-68.
19. Paz-Ares L, Bezares S, Tabernero JM, et al. Review of a promising new agent -pemetrexed disodium. Cancer. 2003;97: 2056-2063. (Pubitemid 36397246)
20. Yamato I, Sho M, Nomi T, et al. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer. 2009;101:1709-1716.
21. Loos M, Hedderich M, Ottenhausen N, et al. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer. 2009;9:463-473.
22. Plate JMD, Plate AE, Shott S, et al. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother. 2005;54:915-925. (Pubitemid 40991334)
23. Pross HF, Baines MG, Rubin P, et al. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. Ix. The quantitation of natural killer cell activity. J Clin Immunol. 1981;1:51-63. (Pubitemid 12064720)
24. Gong J, Chen D, Kashiwaba M, et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997;3:558-561. (Pubitemid 27198656)
25. Friedman M. The use of ranks to avoid the assumption of normality implicit in the analysis of variance. J Am Stat Assoc. 1937;32:675-701.
26. Rodgers J, Nicewander W. Thirteen ways to look at the correlation coefficient. Am Stat. 1988;42:59-66.
27. Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005;16:1639-1645. (Pubitemid 41510138)
28. Boehm U, Klamp T, Groot M, et al. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997;15:749-795.
29. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon I○ FN-gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci. 1998;95:7556-7561. (Pubitemid 28293291)
30. McKinstry KK, Strutt TM, Swain SL. The potential of CD4 T-cell memory. Immunology. 2010;130:1-9.
31. Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-IFN-gamma: implications for immune responses and autoimmune diseases. Immunity. 2009;31:539-550.
32. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612-1616.
33. Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2:269-274. (Pubitemid 33706005)
34. Loos M, Hedderich DM, Friess H, et al. B7-H3 and its role in antitumor immunity. Clin Dev Immunol. 2010;2010:1-7.
35. Chaput N, Louafi S, Bardier A, et al. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut. 2009;58:520-529.
36. Li J, Huang Z-F, Xiong G, et al. Distribution, characterization, and induction of CD8+ regulatory T cells and IL-17-producing CD8+ T cells in nasopharyngeal carcinoma. J Transl Med. 2011;9:189-199.
37. Kiniwa Y, Miyahara Y, Wang HY, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007;13:6947-6958. (Pubitemid 350276874)